One-sided price-cut plan should be reconsidered, a lawmaker says

Published: 2009-10-09 06:59:00

Updated: 2009-10-09 06:59:00

The government will have to reconsider its scheme to press pharmaceutical firms to lower drug prices, which is likely to damage the profits of the domestic medical sector, a lawmaker claimed.

"We can't agree that pharmaceutical companies and medical institutions are solely responsible for the ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK